Patents by Inventor Kenneth M. Ferguson
Kenneth M. Ferguson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230226178Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.Type: ApplicationFiled: February 28, 2023Publication date: July 20, 2023Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
-
Patent number: 11628217Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.Type: GrantFiled: August 30, 2017Date of Patent: April 18, 2023Assignee: OMEROS CORPORATIONInventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
-
Publication number: 20190062455Abstract: The present invention relates to therapeutic methods of using stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, and kits comprising the formulations for treating subjects suffering from atypical hemolytic uremic syndrome (aHUS).Type: ApplicationFiled: August 21, 2018Publication date: February 28, 2019Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
-
Publication number: 20180153988Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.Type: ApplicationFiled: August 30, 2017Publication date: June 7, 2018Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
-
Patent number: 9850238Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3, 5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.Type: GrantFiled: October 12, 2016Date of Patent: December 26, 2017Assignee: Omeros CorporationInventors: Neil S. Cutshall, Kenneth M. Ferguson, Charles Prince Zuta
-
Publication number: 20170096420Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.Type: ApplicationFiled: October 12, 2016Publication date: April 6, 2017Inventors: Neil S. Cutshall, Kenneth M. Ferguson, Charles Prince Zuta
-
Patent number: 9493447Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.Type: GrantFiled: April 24, 2015Date of Patent: November 15, 2016Assignee: Omeros CorporationInventors: Neil S. Cutshall, Kenneth M. Ferguson, Charles Prince Zuta
-
Publication number: 20160024070Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-y1)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.Type: ApplicationFiled: April 24, 2015Publication date: January 28, 2016Inventors: Neil S. CUTSHALL, Kenneth M. FERGUSON, Charles Prince ZUTA
-
Patent number: 6613768Abstract: A method of treating female arousal disorder (FAD) in a female patient is disclosed. The method includes orally administering an agent that inhibits cyclic guanosine 3′5′-monophosphate specific phosphodiesterase type 5 to the female patient.Type: GrantFiled: October 19, 2001Date of Patent: September 2, 2003Assignee: Lilly ICOS LLCInventors: Lora L. Allemeier, Diane L. Brashear, Kenneth M. Ferguson, William E. Pullman
-
Publication number: 20030144296Abstract: The present invention relates to phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 10 mg unit dosage are useful for the treatment of sexual dysfunction by daily administration of the PDE5 inhibitor. The articles of manufacture described herein are characterized by PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, especially erectile dysfunction, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes and with an improvement of vascular conditioning.Type: ApplicationFiled: January 14, 2003Publication date: July 31, 2003Applicant: Lilly ICOS LLCInventors: John S. Whitaker, Inigo Saenz de Tejada, Kenneth M. Ferguson
-
Publication number: 20030100478Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction. The articles of manufacture described herein are characterized by selective PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes.Type: ApplicationFiled: July 19, 2002Publication date: May 29, 2003Applicant: Lilly ICOS LLCInventors: Jeffrey T. Emmick, Kenneth M. Ferguson, William E. Pullman, John S. Whitaker
-
Publication number: 20030054992Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: ApplicationFiled: April 3, 2002Publication date: March 20, 2003Applicant: ICOS CorporationInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 6451807Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in methods of treating sexual dysfunction in individuals suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction.Type: GrantFiled: April 26, 2000Date of Patent: September 17, 2002Assignee: Lilly Icos, LLC.Inventors: Jeffrey T. Emmick, Kenneth M. Ferguson, William E. Pullman, John S. Whitaker
-
Publication number: 20010053780Abstract: The present invention relates to phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic quanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 10 mg unit dosage are useful for the treatment of sexual dysfunction by daily administration of the PDE5 inhibitor. The articles of manufacture described herein are characterized by PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, especially erectile dysfunction, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes and with an improvement of -vascular conditioning.Type: ApplicationFiled: April 13, 2001Publication date: December 20, 2001Inventors: John S. Whitaker, Inigo Saenz de Tejada, Kenneth M. Ferguson
-
Patent number: 6037119Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: March 14, 2000Assignee: Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 5955583Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Antibodies to the cGMP-binding, cGMP-stimulated phosphodiesterase are disclosed. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 1999Assignees: ICOS Corporation, Board of Regents of the University of Washington, Vanderbilt UniversityInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 5702936Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: May 27, 1994Date of Patent: December 30, 1997Assignees: ICOS Corporation, Vanderbilt University, Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 5652131Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: June 7, 1995Date of Patent: July 29, 1997Assignees: ICOS Corporation, Vanderbilt University, Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas